Table 1.
Clinical characteristics of the 115 participants, N = 115(%)
| Women | 40 (34.8) |
|---|---|
| Median age in years (IQR) | 50 (35–63) |
| At least one comorbidity | 41 (35.7) |
| Comorbidities | |
| Obesity | 15 (13) |
| Diabetes | 18 (15.7) |
| High blood pressure | 13 (11.3) |
| Chronic renal failure | 4 (3.5) |
| Previous cardiovascular events | 3 (2.6) |
| Patients living with HIV | 11 (9.7) |
| Type of hematologic malignancy: | |
| Acute myeloid leukemia | 12 (10.4) |
| Acute lymphoblastic leukemia | 16 (14) |
| Non-Hodgkin Lymphoma | 60 (52.2) |
| Hodgkin Lymphoma | 12 (10.4) |
| Myeloma/plasmacytoma | 9 (7.8) |
| Myelodysplastic syndrome | 2 (1.7) |
| Chronic lymphocytic leukemia | 4 (3.5) |
| Active neoplasia | 96 (83.5) |
| SARS COV2 vaccination status (n = 114) | |
| Not vaccinated | 26 (22.8) |
| One dose | 15 (13.2) |
| Two doses | 50 (43.8) |
| Three doses | 23 (20.2) |
| Bone marrow transplant | 10 (8.7) |
| Chemotherapy < 30 days | 54 (47) |
| Rituximab in the last six months | 35 (30.4) |
| Median of days since rituximab, (IQR) | 46 (15–134) |